Next Article in Journal
Successful Use of Metronomic Vinblastine and Fluorothymidine pet Imaging for the Management of Intramedullary Spinal Cord Anaplastic Oligoastrocytoma in a Child
Previous Article in Journal
Two Cases of Cutaneous Drug Eruption Associated with Temozolomide Therapy for Glioblastoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 21
Issue 6
10.3747/co.21.2144
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Gemcitabine-Based Regimen for Primary Ovarian Angiosarcoma with MYC Amplification

by
I. Yonezawa
1,
M. Waki
2,
Y. Tamura
1,
R. Onoda
1,
M. Narushima
1,
T. Ishizuka
1 and
S. Tajima
3,*
1
Obstetrics and Gynecology, Shizuoka Saiseikai General Hospital, Shizuoka, Japan
2
Cell Biology and Anatomy, Hamamatsu University School of Medicine, Shizuoka, Japan
3
Pathology, Shizuoka Saiseikai General Hospital, Shizuoka, Japan
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(6), 782-789; https://doi.org/10.3747/co.21.2144
Submission received: 3 September 2014 / Revised: 9 October 2014 / Accepted: 11 November 2014 / Published: 1 December 2014

Abstract

Angiosarcoma is a rare and aggressive type of sarcoma, and primary angiosarcoma of the ovary is extremely rare. We report the case of a 29-year-old woman who was diagnosed with ovarian angiosarcoma and possible bone metastases. We treated this patient with a gemcitabine-based regimen as postoperative adjuvant chemotherapy, after which she achieved at least 7 years of progression-free survival, an extremely long duration given the aggressive features of this tumour. We retrospectively performed immunohistochemical analyses and fluorescence in situ hybridization to make a pathology diagnosis and to investigate the tumour features. MYC amplification and c-Myc protein overexpression were positively detected. It might be possible to correlate the effectiveness of the gemcitabine-based chemotherapeutic regimen with MYC gene amplification and c-Myc protein overexpression.
Keywords: angiosarcoma; mucinous cystadenoma; surgical resection; chemotherapy; gemcitabine; MYC angiosarcoma; mucinous cystadenoma; surgical resection; chemotherapy; gemcitabine; MYC

Share and Cite

MDPI and ACS Style

Yonezawa, I.; Waki, M.; Tamura, Y.; Onoda, R.; Narushima, M.; Ishizuka, T.; Tajima, S. Gemcitabine-Based Regimen for Primary Ovarian Angiosarcoma with MYC Amplification. Curr. Oncol. 2014, 21, 782-789. https://doi.org/10.3747/co.21.2144

AMA Style

Yonezawa I, Waki M, Tamura Y, Onoda R, Narushima M, Ishizuka T, Tajima S. Gemcitabine-Based Regimen for Primary Ovarian Angiosarcoma with MYC Amplification. Current Oncology. 2014; 21(6):782-789. https://doi.org/10.3747/co.21.2144

Chicago/Turabian Style

Yonezawa, I., M. Waki, Y. Tamura, R. Onoda, M. Narushima, T. Ishizuka, and S. Tajima. 2014. "Gemcitabine-Based Regimen for Primary Ovarian Angiosarcoma with MYC Amplification" Current Oncology 21, no. 6: 782-789. https://doi.org/10.3747/co.21.2144

APA Style

Yonezawa, I., Waki, M., Tamura, Y., Onoda, R., Narushima, M., Ishizuka, T., & Tajima, S. (2014). Gemcitabine-Based Regimen for Primary Ovarian Angiosarcoma with MYC Amplification. Current Oncology, 21(6), 782-789. https://doi.org/10.3747/co.21.2144

Article Metrics

Back to TopTop